New Studies Suggest HPV Vaccine Reduces Head and Neck Cancers in Men: Significant Decrease in Throat and Mouth Cancer Risk

Philadelphia, Pennsylvania United States of America
CDC recommends HPV vaccination for adolescent boys since 2011, with catch-up shots available for anyone through age 26 who hasn't been vaccinated
England's HPV vaccination program leads to significant decrease in cervical cancer and CIN3 across socioeconomic groups
HPV vaccination rates among adolescents and young adults in the US have improved from 7.8% to 36.4% for males and from 37.7% to 49.4% for females between 2011 and March 2020
HPV vaccine is effective in preventing penile, anal, and vaginal cancers
HPV vaccine protects against strains of the virus linked to throat and mouth cancer
Males are about twice as likely to develop head and neck cancers than women
Merck's sales of the HPV vaccine grew by 29% to $8.9 billion in the last year
New studies suggest HPV vaccine reduces head and neck cancers in men
No cases of cervical cancer were found in women who were vaccinated before they were 14 years old
New Studies Suggest HPV Vaccine Reduces Head and Neck Cancers in Men: Significant Decrease in Throat and Mouth Cancer Risk

In a significant development, new studies suggest that the Human Papillomavirus (HPV) vaccine not only prevents cervical cancer in women but also reduces the risk of head and neck cancers in men. The HPV vaccine has been shown to protect against strains of the virus linked to various types of cancer, including those affecting the throat and mouth.

According to a study published in BMJ, England's HPV vaccination program has led to a significant decrease in cervical cancer and grade 3 cervical intraepithelial neoplasia (CIN3) across socioeconomic groups. The highest reduction was observed among females with the highest vaccination uptake and youngest age at immunization.

Another study, published in the American Society of Clinical Oncology conference, found that HPV vaccination rates among males have been increasing and lag behind those of females but are accelerating. The researchers noted that men are about twice as likely to develop head and neck cancers than women, making this a crucial development.

The Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for adolescent boys since 2011, with catch-up shots available for anyone through age 26 who hasn't been vaccinated. The vaccine has been shown to protect against strains of the virus linked to cervical cancer and has significantly reduced rates of this cancer.

The HPV vaccine is also effective in preventing penile, anal, and vaginal cancers. A study published in Stat News reported that no cases of cervical cancer were found in women who were vaccinated before they were 14 years old. The researchers noted that the highest decrease in cervical cancer and CIN3 was observed among females with the highest vaccination uptake and youngest age at immunization.

Despite these findings, HPV vaccination rates among adolescents and young adults in the US have improved from 7.8% to 36.4% for males and from 37.7% to 49.4% for females between 2011 and March 2020.

Merck's sales of the HPV vaccine grew by 29% to $8.9 billion in the last year, indicating a growing awareness and acceptance of the importance of HPV vaccination.

It is important to note that while these studies suggest a significant reduction in cancer risk associated with HPV vaccination, more research is needed to fully understand its long-term effects and potential benefits.

Sources:

  1. BMJ: Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study.
  2. Stat News: New data show the HPV vaccine prevents cancer in men, too. Why don't more people get it?
  3. Time: HPV Vaccines Prevent Cancer in Men as Well as Women

Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image
Article Image

Confidence

96%

Doubts
  • Are there any long-term side effects of the HPV vaccine that have not been fully studied yet?
  • Do all strains of HPV that cause head and neck cancers in men respond to the HPV vaccine?
  • What is the most effective age for administering the HPV vaccine for maximum protection against cancer?

Sources

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The HPV vaccine prevents head and neck cancers in men, study suggests

NBC News Digital Friday, 24 May 2024 07:29
  • Unique Points
    • HPV vaccine reduces the overall risk of HPV-related cancers in males by 54%
    • HPV is linked to head and neck cancers, which affect the throat and mouth, accounting for up to 70% of these cancers in men
    • Men are about twice as likely to develop head and neck cancers than women
    • HPV vaccine protects against strains of the virus linked to cervical cancer and has been found to significantly reduce rates of this cancer
    • HPV is also linked to penile, anal, and vaginal cancers
    • The HPV vaccine was initially approved for adolescent girls but now protects males as well
    • HPV vaccination rates among males are increasing and lag behind females but are accelerating
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication

96%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

HPV Vaccines Prevent Cancer in Men as Well as Women

TIME Magazine CARLA K. Friday, 24 May 2024 07:30
  • Unique Points
    • From 2011 to 2020, HPV vaccination rates rose from 8% to 36% among males.
    • HPV vaccine recommended for boys since 2011, catch-up shots for anyone through age 26 who hasn’t been vaccinated.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (95%)
    The article makes several statements that are supported by data and research. There is no clear evidence of any logical fallacies in the text. However, there are a few instances of inflammatory rhetoric used to emphasize the importance of HPV vaccination for both men and women.
    • These cancers take years to develop so the numbers were low:
    • Results of the study and a second were released Thursday by the American Society of Clinical Oncology and will be discussed next month at its annual meeting in Chicago.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

97%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

New data show the HPV vaccine prevents cancer in men, too. Why don't more people get it?

STAT News Matthew Herper Thursday, 23 May 2024 21:16
  • Unique Points
    • New data from ASCO shows that the HPV vaccine reduces the risk of HPV-related cancers by 56% in men and 36% in women.
    • A study found that no cases of cervical cancer were found in women who were vaccinated before they were 14 years old.
    • Rates of HPV vaccination in adolescents and young adults in the US improved from 7.8% to 36.4% for males and from 37.7% to 49.4% for females between 2011 and March 2020.
    • Merck’s sales of the HPV vaccine grew by 29% to $8.9 billion in the last year.
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (85%)
    The article contains several appeals to authority and inflammatory rhetoric. It cites the American Society of Clinical Oncology and the Centers for Disease Control and Prevention without providing specific statements that would be fallacious, but it does use strong language to criticize vaccine hesitancy and suggest that more people should be getting the HPV vaccine. The author also makes a dichotomous depiction by presenting vaccinated vs unvaccinated rates of HPV-linked cancer, implying a false dilemma between accepting the vaccine or facing increased cancer risk.
    • It’s a shame.
    • But it’s a shame. Merck did its fair share of inadvisable political jockeying when it came to launching Gardasil, and it has certainly reaped profits from selling the vaccine; sales grew 29% to $8.9 billion last year.
    • There is not really any debate, at this point, that this vaccine would prevent tens of thousands of cases of cancer a year if it were used more widely.
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (100%)
    None Found At Time Of Publication

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermine the credibility of the source. It is calculated as:
(Site Conflicts Of Interest + Author Conflicts Of Interest) / 2.0 * 0.2 + ArticleBiasScore * 0.20 + UniquePointsScore * 0.05 + DeceptionScore * 0.20 + ReadabilityScore * 0.05 + FallacyScore * 0.20

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

Cervical cancer rates drop significantly among vaccinated women

News Medical Net Thursday, 16 May 2024 12:24
  • Unique Points
    • HPV vaccination introduced in England in 2008 has reduced cervical cancer and CIN3 prevalence
    • HPV vaccine coverage has been consistently high
    • The highest decrease in cervical cancer and CIN3 was observed among females with the highest vaccination uptake and youngest age at immunization
    • Cervical screening uptake is low among younger females in poorest regions, resulting in lower detection rates of screen-identified cervical cancers and CIN3
    • HPV vaccine has saved predicted 687 cervical malignancies and 23,192 CIN3s by the middle of 2020
    • The highest cervical cancer rates were among females from the most socioeconomically deprived regions (192 and 199 for first and second fifths, respectively)
    • CIN3 incidences decreased more among females receiving catch-up vaccinations in least socioeconomically deprived regions than in most
    • The number of women with CIN3 averted was highest among women living in the most impoverished areas (5,121 and 5,773 for first and second fifths, respectively)
    • HPV vaccination program had a significant impact across all socioeconomic levels
    • The efficacy of national HPV immunization persisted in the extra year of follow-up (July 2019 to June 2020)
  • Accuracy
    No Contradictions at Time Of Publication
  • Deception (100%)
    None Found At Time Of Publication
  • Fallacies (100%)
    None Found At Time Of Publication
  • Bias (100%)
    None Found At Time Of Publication
  • Site Conflicts Of Interest (100%)
    None Found At Time Of Publication
  • Author Conflicts Of Interest (0%)
    None Found At Time Of Publication